Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW B GENTRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1922072560
CMS profile
503391
Location
BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$613.07

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $613.07 28

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW B GENTRY

NPI 1922072560 · CMS profile ID 503391

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922072560?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922072560?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922072560?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1922072560?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $613.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $5.8712/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913704 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.5512/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223905596 CMS
Ipsen Biopharmaceuticals, Inc $22.7511/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208836250 CMS
GENZYME CORPORATION $23.0010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233668324 CMS
Janssen Biotech, Inc. $17.8410/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175036626 CMS
AstraZeneca Pharmaceuticals LP $13.7909/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206692221 CMS
Regeneron Healthcare Solutions, Inc. $22.4009/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212926595 CMS
Aimmune Therapeutics, Inc. $19.2809/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249660415 CMS
ABBVIE INC. $8.6909/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913702 CMS
ABBVIE INC. $3.3208/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913700 CMS
ABBVIE INC. $21.1108/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913698 CMS
Boston Scientific Corporation $68.5008/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181427448 CMS
ABBVIE INC. $4.5808/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913696 CMS
PFIZER INC. $14.3207/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229028767 CMS
ABBVIE INC. $8.5106/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913694 CMS
ABBVIE INC. $6.8006/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913692 CMS
Ipsen Biopharmaceuticals, Inc $18.2306/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208836248 CMS
PFIZER INC. $20.8406/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228809170 CMS
ABBVIE INC. $20.4005/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913690 CMS
PFIZER INC. $18.5405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231706821 CMS
Ardelyx, Inc. $135.9504/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247849474 CMS
ABBVIE INC. $5.9904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913688 CMS
ABBVIE INC. $12.9604/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913686 CMS
ABBVIE INC. $18.4003/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913684 CMS
TerSera Therapeutics LLC $14.9503/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244053678 CMS
Aimmune Therapeutics, Inc. $22.5002/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249660417 CMS
ABBVIE INC. $20.7601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913682 CMS
ABBVIE INC. $16.2401/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201913680 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $393.23 22
PY2020 $142.24 6
PY2021 $293.32 9
PY2022 $603.61 24
PY2023 $273.73 14
PY2024 $414.03 15
PY2025 $613.07 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $154,413.55 9
PY2022 Principal investigator $564,732.27 36
PY2021 Recipient $140.50 1
PY2021 Principal investigator $488,808.99 57
PY2020 Principal investigator $877,751.94 34
PY2019 Recipient $410.95 1
PY2019 Principal investigator $141,659.45 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,732.95 12/29/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832566006
Principal investigator 1 PFIZER INC. $2,010.45 12/28/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832565219
Principal investigator 1 PFIZER INC. $670.15 12/24/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832565229
Principal investigator 1 PFIZER INC. $6,767.18 12/22/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832566015
Principal investigator 1 PFIZER INC. $2,495.71 12/07/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832565995
Principal investigator 1 PFIZER INC. $2,139.80 12/01/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832565599
Principal investigator 1 PFIZER INC. $1,340.30 11/24/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832711167
Principal investigator 1 PFIZER INC. $21,657.35 11/23/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832657595
Principal investigator 1 PFIZER INC. $670.15 11/10/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832841071
Principal investigator 1 PFIZER INC. $670.15 10/30/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832741771
Principal investigator 1 PFIZER INC. $3,738.80 10/16/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832862801
Principal investigator 1 PFIZER INC. $3,705.00 10/09/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832893663
Principal investigator 1 PFIZER INC. $3,653.36 10/08/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832658859
Principal investigator 1 PFIZER INC. $12,898.70 10/08/2021 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832698802
Principal investigator 1 PFIZER INC. $500.00 10/08/2021 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832789781
Principal investigator 1 PFIZER INC. $8,721.70 10/05/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832767423
Principal investigator 1 PFIZER INC. $9,560.20 09/25/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832698367
Principal investigator 1 PFIZER INC. $2,398.50 09/21/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832721841
Principal investigator 1 PFIZER INC. $12,762.24 09/15/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832657614
Principal investigator 1 PFIZER INC. $9,075.95 09/14/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832854541
Principal investigator 1 PFIZER INC. $2,488.85 09/08/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832893651
Principal investigator 1 PFIZER INC. $13,872.66 08/27/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832657605
Principal investigator 1 PFIZER INC. $670.15 08/24/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832854315
Principal investigator 1 PFIZER INC. $55,530.94 08/21/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832657585
Principal investigator 1 PFIZER INC. $2,010.45 08/14/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832868293
Principal investigator 1 PFIZER INC. $1,148.55 08/07/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832915811
Principal investigator 1 Eli Lilly and Company $26,250.00 08/03/2021 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 819453713
Principal investigator 1 PFIZER INC. $5,264.35 08/03/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832816529
Principal investigator 1 PFIZER INC. $4,785.95 07/24/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832759433
Principal investigator 1 PFIZER INC. $15,700.00 07/21/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832658665
Principal investigator 1 PFIZER INC. $670.15 07/13/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832809585
Principal investigator 1 PFIZER INC. $1,502.80 06/26/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832764363
Principal investigator 1 PFIZER INC. $3,340.30 06/22/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832849387
Principal investigator 1 PFIZER INC. $670.15 06/12/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832793847
Principal investigator 1 PFIZER INC. $3,168.10 05/29/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832718247
Recipient Eli Lilly and Company $140.50 05/25/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 819443343
Principal investigator 1 PFIZER INC. $832.65 05/15/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832835323
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $50.00 05/13/2021 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
MCP-103-205 No dispute reported 06/30/2026 831593753
Principal investigator 1 PFIZER INC. $3,320.85 05/08/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832784665
Principal investigator 1 PFIZER INC. $4,211.35 05/01/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832738221
Principal investigator 1 PFIZER INC. $2,009.80 04/24/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832758541
Principal investigator 1 PFIZER INC. $4,469.40 04/17/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832857206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36.00 04/15/2021 Non-covered Recipient Entity
BOZEMAN HEALTH CLINICAL RESEAR
ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS: DB, MAINTENANCE No dispute reported 06/30/2026 816709355
Principal investigator 1 PFIZER INC. $5,166.20 04/10/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832872065
Principal investigator 1 PFIZER INC. $18,689.45 04/03/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832849379
Principal investigator 1 PFIZER INC. $26,865.80 03/27/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832806599
Principal investigator 1 PFIZER INC. $10,082.15 03/20/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832914607
Principal investigator 1 PFIZER INC. $13,773.50 03/13/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832797727
Principal investigator 1 PFIZER INC. $36,991.50 03/06/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832915979
Principal investigator 1 PFIZER INC. $1,215.50 02/27/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832836967
Principal investigator 1 PFIZER INC. $97,601.85 02/20/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832858991
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $50.00 02/16/2021 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
MCP-103-205 No dispute reported 06/30/2026 831594928
Principal investigator 1 PFIZER INC. $3,838.25 02/13/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832874527
Principal investigator 1 PFIZER INC. $1,340.30 02/06/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832739627
Principal investigator 1 PFIZER INC. $2,172.95 01/30/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832811271
Principal investigator 1 PFIZER INC. $2,010.45 01/23/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832745657
Principal investigator 1 PFIZER INC. $4,000.75 01/16/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832899667
Principal investigator 1 PFIZER INC. $3,838.25 01/08/2021 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832892487